CLL & Lymphoma
EU Focus Meeting 2026
📍 SANA Malhoa Hotel, Av. José Malhoa 8, 1099-089 Lisbon, Portugal
🗓️ March 13 - 14, 2026
Last Year's Highlights
The CLL & Lymphoma EU Focus Meeting 2026 will take place on March 13–14, 2026,
This educational meeting is designed to address ongoing learning needs in the management of chronic lymphocytic leukaemia and lymphoid malignancies, particularly in light of emerging clinical data, evolving treatment strategies, and their application in routine clinical practice. The programme theme, “Updating Knowledge & Clinical Practice in 2026,” reflects the objective of supporting evidence-based decision-making and improving patient care.
The meeting is intended for haematologists, oncologists, and other healthcare professionals involved in the diagnosis, treatment, and long-term management of patients with CLL and lymphoma.
The scientific programme will consist of expert-led presentations, moderated panel discussions, and structured roundtable sessions to facilitate peer-to-peer scientific exchange. All content is developed to be independent, balanced, and scientifically objective, based on current clinical evidence and guidelines, and free from promotional influence.
All faculty have been selected by the chairs of the meeting and have disclosed any relevant conflicts of interest.
Sponsors have had no influence on the programme content, speaker selection, or educational materials.
Learning Objectives:
By the end of this meeting, participants should be able to:
-
Evaluate emerging clinical and biological data influencing current and future treatment strategies in CLL and major lymphoma subtypes, including LBCL, follicular lymphoma, mantle cell lymphoma, and T-cell lymphomas.
-
Assess mechanisms of treatment resistance and disease progression, including failure after CAR-T therapy, Richter transformation, and double-exposed or double-refractory CLL, and consider evidence-based management approaches.
-
Apply prognostic and predictive biomarkers (including molecular classification, cell of origin, and MRD assessment) to inform therapeutic decision-making across different disease stages and lines of therapy.
-
Compare front-line and subsequent treatment sequencing strategies, including continuous versus fixed-duration approaches, targeted therapies, immunochemotherapy, and transplant-based strategies, with consideration of long-term outcomes.
-
Discuss the role of novel and emerging therapies, such as bispecific antibodies, CAR-based approaches, non-covalent BTK inhibitors, BCL2 inhibitors, and new combination strategies in CLL and lymphoma.
-
Integrate evolving standards of care with patient-centred considerations, including treatment tolerability, disease biology, and real-world clinical scenarios, to optimise outcomes along the patient journey.
Chairs of Cell Therapy & Bispecifics US Focus Meeting 2026:
Stephan Stilgenbauer, MD
Comprehensive Cancer Center Ulm, Ulm University, Germany
Franck Morschhauser, MD
Centre Hospitalier Universitaire de Lille, France
Supporters to be announced...
Interested in supporting this meeting? Get in contact:
neve.rowlands@md-education.com
Agenda & Faculty
March 13, 2026 | Day 1
Session I: Current Challenges in LBCL
Moderated by:
Daniel Hodson, MD
University of Cambridge, UK
VC
Vincent Camus, MD
Henri Becquerel Centre, Rouen, France
Gloria Iacoboni, MD
University Hospital Vall d’Hebron, Barcelona, Spain
Daniel Hodson, MD
University of Cambridge, UK
Session II: T-Cell NHL
Moderated by:
Emmanuel Bachy, MD
Lyon Cancer Research Center, France
Laurence de Leval, MD
Institut Universitaire de Pathologie, Lausanne, Switzerland
SL
Stefano Luminari, MD
University of Modena and Reggio Emilia, Modena, Italy
EB
Estelle Bourbon, MD
Hospices Civils de Lyon, France
Session III: Follicular Lymphoma
Moderated by:
Franck Morschhauser, MD
Centre Hospitalier Universitaire de Lille, France
Emmanuel Bachy, MD
Lyon Cancer Research Center, France
Camille Laurent, MD
Toulouse Cancer Research Center, France
Jessica Okosun, MD
Barts Cancer Institute, London, UK
Session IV: Mantle Cell Lymphoma: The Great Debate: Which Front Line Therapy Results into Best Long-term Outcome for Patient Subgroups when also Considering Salvage Strategies - Thinking Beyond PFS1!
Moderated by:
Steven Le Gouill, MD
Institut Curie, Paris, France
Toby Eyre, MD
Oxford University Hospitals NHS Foundation Trust, UK
SG
Steven Le Gouill, MD
Institut Curie, Paris, France
Mats Jerkeman, MD
Lund University, Sweden
March 14, 2026 | Day 2
Session V: Combining Biological Insights and Therapeutic Advances to Improve CLL Outcomes
Moderated by:
Paolo Ghia, MD
Università Vita-Salute San Raffaele, Milan, Italy
DR
Davide Rossi, MD
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Vincent Lévy, MD
Avicenne Hospital, Bobigny, France
DR
Davide Rossi, MD
Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Session VI: The Patient Journey in the Treatment Sequence – Standards of Care and Perspectives
Moderated by:
George Follows, MD
Cambridge University Hospitals NHS Foundation Trust, UK
KF
Kirsten Fischer, MD
University Hospital Cologne, Germany
Francesc Bosch, MD
University Hospital Vall d’Hebron, Barcelona, Spain
CN
Thomas Chatzikonstantinou, MD
Center for Research and Technology Hellas (CERTH), Thessaloniki, Greece
Session VII: The Great Debate: Which Front Line Therapy Results into Best Long-term Outcome for Patient Subgroups when also Considering Salvage Strategies – Thinking Beyond PFS1!
Moderated by:
Francesc Bosch, MD
University Hospital Vall d’Hebron, Barcelona, Spain
Alessandra Tedeschi, MD
Niguarda Hospital, Milan, Italy
OA
Othman Al-Sawaf, MD
University Hospital Cologne, Germany
GF
George Follows, MD
Cambridge University Hospitals NHS Foundation Trust, UK
Session VIII: What is the Next Therapeutic Revolution?
Moderated by:
Kirsten Fischer , MD
University Hospital Cologne, Germany
Arnon Kater, MD
University of Amsterdam, Netherlands
Paolo Ghia, MD
Università Vita-Salute San Raffaele, Milan, Italy
LS
Lydia Scarfo, MD
Università Vita-Salute San Raffaele, Milan, Italy
Neve Rowlands
Project Manager
How long has Neve Rowlands been in the business?
Neve Rowlands has been with MD Education since 2023
About Neve Rowlands
I am a dedicated project manager in the hematology industry, with a current focus on CLL and lymphoma. Specialising in logistical organisation with a sharp eye for detail, and committed to delivering high-quality, seamless events. The most rewarding part of the role is watching meetings come to life. I am passionate about connecting with both familiar and new faces, and driven by the impact of well-executed projects that support meaningful progress in the field.
